On November 30, 2020, IMPACT Therapeutics, Inc. closed the transaction. The company received $50,000,000 in its series C+ round of funding led by Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877). The transaction also included participation from Shenzhen Capital Group Co., Ltd., Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) and existing investors Lilly Asia Ventures and China Summit Capital.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.74 HKD | +4.88% | +16.23% | -44.75% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.75% | 2.99B | |
-4.66% | 87.53B | |
+1.32% | 40.42B | |
-19.27% | 29.48B | |
+57.86% | 25.43B | |
-17.69% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- 1877 Stock
- News Shanghai Junshi Biosciences Co., Ltd.
- IMPACT Therapeutics, Inc. announced that it has received $50 million in funding from Shanghai Junshi Biosciences Co., Ltd., Shenzhen Capital Group Co., Ltd., Lilly Asia Ventures, Zhejiang Ausun Pharmaceutical Co., Ltd., China Summit Capital